Stifel Nicolaus Reiterates $36.00 Price Target for Vanda Pharmaceuticals (VNDA)
Stifel Nicolaus set a $36.00 price target on Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note released on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on VNDA. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a strong-buy rating to a hold rating in a report on Wednesday, August 8th. Cantor Fitzgerald assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, August 22nd. They issued a neutral rating and a $26.00 price objective on the stock. Oppenheimer assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday, September 20th. They issued a buy rating and a $29.00 price objective on the stock. CIBC reaffirmed an outperform rating on shares of Vanda Pharmaceuticals in a report on Friday, September 21st. Finally, Citigroup increased their price objective on shares of Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a buy rating in a report on Tuesday, October 16th. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. Vanda Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $33.00.
Vanda Pharmaceuticals stock opened at $28.94 on Monday. Vanda Pharmaceuticals has a 1 year low of $13.30 and a 1 year high of $33.44. The stock has a market capitalization of $1.31 billion, a PE ratio of -82.69, a price-to-earnings-growth ratio of 4.28 and a beta of 0.87.
Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its holdings in shares of Vanda Pharmaceuticals by 2.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock worth $32,028,000 after acquiring an additional 41,200 shares during the period. BlackRock Inc. increased its stake in Vanda Pharmaceuticals by 16.3% during the 2nd quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock valued at $94,506,000 after buying an additional 693,922 shares during the period. Xact Kapitalforvaltning AB acquired a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $240,000. PNC Financial Services Group Inc. increased its stake in Vanda Pharmaceuticals by 25.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 279,485 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 55,911 shares during the period. Finally, Virginia Retirement Systems ET AL acquired a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $754,000. 99.33% of the stock is currently owned by institutional investors and hedge funds.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
See Also: How Does the Quiet Period Work?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.